Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | -5.52% | -8.19% | +119.59% |
May. 02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 390K | Sales 2025 * | 66.67K | Capitalization | 145M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -57M | EV / Sales 2024 * | 373 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2,180 x |
P/E ratio 2024 * |
-3.32
x | P/E ratio 2025 * |
-3.07
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.33% |
Latest transcript on Cardiff Oncology, Inc.
1 day | -5.52% | ||
1 week | -8.19% | ||
Current month | -25.46% | ||
1 month | -20.15% | ||
3 months | +78.57% | ||
6 months | +160.00% | ||
Current year | +119.59% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 3.25 | -5.52% | 670,535 |
24-05-24 | 3.44 | +4.24% | 398,929 |
24-05-23 | 3.3 | -4.62% | 489,835 |
24-05-22 | 3.46 | -2.26% | 337,044 |
24-05-21 | 3.54 | 0.00% | 551,459 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+119.59% | 145M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+40.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- CRDF Stock